Sick Dividends

Searching For Healthy Profits In The Stock Market

ZOETIS, INC: A PROFITABLE PET PROJECT

Zoetis Inc Pet Stock

 

By Grant Bailey, Equity Analyst 

 

If you have a pet of any kind, it’s more likely than not that you’ve bought something from Zoetis. Zoetis is an absolute giant in the pet care industry, boasting a market capitalization of over $55 billion. However, down roughly 50% from their all-time high 4 years ago, Zoetis has been in a free fall. Particularly, they’ve had a rough 2025 to say the least, down 30% this year alone. With Zoetis losing so much stock market value as of late, they might have actually become a fantastic investment opportunity. Let’s look into why.

 

The quantitative analysis of Zoetis is quite intriguing. To start, despite the stock tumbling over the past 4 years, its year-over-year quarterly profit growth has averaged over 5%. As shown by Macrotrends, Zoetis’s profit had plateaued from late 2022 to early 2023, but it has since rebounded in a very impressive manner. With an incredible net profit margin of 28%, Zoetis is operating with absurd efficiency, as also demonstrated by its 25% ROI. While Zoetis’ P/FCF ratio is high at the moment, subject to general market analysis, it becomes a more complex issue than it might seem at face value. The last time Zoetis’ FCF ratio was near this low was 2018. Zoetis seemed headed to the moon from 2019 through 2021, so maybe this “high” P/FCF ratio isn’t really much of a concern. The same could also be said for Zoetis’ P/S ratio. As for its P/B ratio, it was nearly twice its current value back in 2018, and while Zoetis does have a lot of debt, its current debt-to-equity ratio is about a third of what it was in 2018. This shows promising sustainability, and with a dividend payout that has steadily increased every quarter since early 2020 to boot, this stock makes quite a strong case, quantitatively speaking. In an effort to provide some explanations for some of these ratios mentioned, the P/FCF (price-to-free-cash-flow) ratio measures how much investors are paying per dollar of a company’s cash flow, P/B (price-to-book) ratio measures a company’s market value to a company’s book value (total assets minus liabilities), and P/S (price-to-sales) ratio is a measure of a company’s market value relative to a company’s total revenue. Essentially, the P/FCF is important because it indicates a company’s cash flow. The P/B ratio is important because it highlights the value of assets relative to the value of their liabilities and market value. The P/S ratio is important because it reflects a company’s value based on sales. 

From a more qualitative perspective, the pet care industry is looking more and more fruitful. The reason why this industry will likely take off in due course is that people are more and more frequently choosing dogs and cats over children. Crazy, right? But that’s what we are starting to see as a result of the exponentially increasing cost of raising children. Sure, pets are expensive. But compared to children? Far more affordable, obviously. Since Zoetis sells practically every basic pet product imaginable, it would be perfectly reasonable to assume that they’d benefit hugely from this impending pet care boom.

Zoetis’s heavy share price decline, specifically as of late, is primarily due to its Q3 revenue miss and subsequently lowered revenue guidance. While from a short-term point of view, some investors may feel unsettled with this information, I personally don’t see these Q3 results being detrimental to Zoetis’ long-term success.

 

You understand that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the bloggers, information providers, app providers, or their affiliates are advising you personally concerning the nature, potential, value or suitability of any particular security, portfolio of securities, transaction, investment strategy or other matter. To the extent that any of the content published on the Site may be deemed to be investment advice or recommendations in connection with a particular security, such information is impersonal and not tailored to the investment needs of any specific person. You understand that an investment in any security is subject to a number of risks, and that discussions of any security published on the Site will not contain a list or description of relevant risk factors.

The Site is not intended to provide tax, legal, insurance or investment advice, and nothing on the Site should be construed as an offer to sell, a solicitation of an offer to buy, or a recommendation for any security by Sick Dividends or any third party. You alone are solely responsible for determining whether any investment, security or strategy, or any other product or service, is appropriate or suitable for you based on your investment objectives and personal and financial situation. You should consult an attorney or tax professional regarding your specific legal or tax situation.

ACCEPT